Jason Christiansen is the Vice President of Diagnostics for Ignyta. His teams drive the companion diagnostic strategies, test and applications to support Ignyta’s various therapeutic pipelines. This includes testing in Ignyta’s CLIA/QSR laboratory or working to collaborate and develop different platforms among the clinical trial sites. Prior to Ignyta, Dr. Christiansen was Sr. Director of Assay Development at Genoptix/Novartis, bringing multiple testing platforms, including NGS and digital pathology, into clinical use. Earlier, he led operations and diagnostic efforts at other biotechnology companies (i.e., HistoRx, Protedyne, Molecular Staging). He received his PhD in Biophysics from the University of California.
JOIN OUR WEST COAST USA 2018 STRATEGY MEETING
14th May 2018 | The Hyatt Regency Airport, San Francisco, USA
OUR UNIQUE FORMAT
The Oncology Roundtable Discussions Strategy Meeting are for qualified end-users. These include Senior Executives of Oncology/Immuno-Oncology (from medium to large Pharma, Biopharma and Biotech players) in global positions spanning early to phase IV, as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Oncology R&D,Translational Research/Development/Medicine, Clinical Research/Development, Immuno-Oncology, Medical Affairs Oncology,Clinical Pharmacology,Oncology Clinical Biostatistics and Programming, Oncology Clinical Genomics and Computational Biology, Oncology R&D Innovation, Oncology R&D Strategy, Oncology Portfolio/Project Management.
Charles TheuerPresident and Chief Executive Officer
Bijan NejadnikExecutive Vice President and Chief Medical Officer
Galena Biopharma, Inc.
Judy ChouSenior Vice President and Head of Product Supply Biotech
Suhasini IyerSenior Vice President
Development Sciences & Regulatory Affairs, Teneobio, Inc
Lixia WangSenior Vice President
Biometrics, Health Economics and outcome Research, CTI BioPharma
Jason ChristiansenVice President, Diagnostics
Elias KouchakjiVice President, Clinical Development, Drug Safety, and Pharmacovigilance
Siva NarayananVice President and Global Head, Market Access
PTC Therapeutics Inc
Jeffrey HumphreyPresident & Chief Medical Officer
Kwoya Kirin Pharmaceutical Development Inc.
Rakesh DixitVice President
Research & Development, MedImmune
WHAT TO EXPECT
Interactive Roundtable Discussions
Attendees can proactively share and ask questions to their peers about the success of their work in an informal setting.
Director level one-to-one meetings
We provide opportunities to engage with one another in our strategy meeting in a series of pre-arranged business meetings by interacting face to face.
Tailor-fit and Personalized Agenda
Being able to experience different sessions is what makes our event unique that’s why our attendees can personalize and select sessions they want to participate in.
Several networking opportunities are in store for attendees to connect and build new relationships with their peers through luncheons, cocktails and informal introductions.
Thank you for reaching Proventa International
***The information you provided in this website is confidential and the company will strictly forbidden to share any part of these information with any third party without a written consent of the sender.
Our unique strategy meeting platform ensures that delegates can network with peers and benchmark their challenges whilst meeting a select number of supplier organizations that are currently at the forefront of innovation. This in turns helps them to save time and money associated in sourcing the best suppliers to procure solutions in an environment, which is 100% conducive to doing business.
If you are an exciting start-up trying to get your innovation in front global heads from the leading Pharmaceutical companies, or a mature market-leading conglomerate with legacy solutions trying to stay one step ahead of the competition – we are here to help!
WHAT PEOPLE SAY
Chief Information Officer
Its nice because they basically allowed people to engaged to discussions and questions. Academic and industry is very nice and informative
Ivan John Clement
Data Scientist - R&D
Its good because you really get the people to talk. They are willing to share their knowledge, the juniors are very eager to learn.
Manager Quality Assurance
The format is the beginning of breakthrough and integration, the level of delegates is very good and excellent, they learn a lot.
Founder & President
The kind of interaction is very interactive
Director & Professor
Because of diversity we really districts the points and all. People are very diversity and thoughtful in a round table.
Images coming soon
SAN FRANCISCO AIRPORT
1333 Old Bayshore Hwy, Burlingame, CA 94010, USA
OUR MEDIA PARTNERS
President & Chief Medical Officer
Kwoya Kirin Pharmaceutical Development Inc.
Research & Development, MedImmune
President and Chief Executive Officer, Tracon Pharmaceuticals
Dr. Theuer joined TRACON as President, Chief Executive Officer, and a board member in July 2006. From 2004 to 2006, Dr. Theuer was Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc. where he led the of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Dr. Theuer was the Director of Clinical Oncology at Pfizer, where he led the clinical of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals and the National Cancer Institute where he was involved in the of multiple small molecules and monoclonal antibody therapies. Dr. Theuer holds a B.S. from MIT, an M.D. from UC San Francisco, and a Ph.D. from UC Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center. Dr. Theuer has held academic positions at the National Cancer Institute and at the University of California, Irvine, where he was a member of the Division of Surgical Oncology. His previous research involved immunotoxin and cancer vaccine , translational work in cancer patients, and gastrointestinal cancer epidemiology.
Executive Vice President and Chief Medical Officer, Galena Biopharma, Inc.
Senior Vice President and Head of Product Supply Biotech, Bayer Pharmaceuticals
With more than 20 years of industry experience in biomanufacturing and drug , Dr. Judy Chou currently heads the global Pharmaceutical Product SupplyBiotech organization overseeing the manufacturing and distribution of Bayer’s $3 billion biotechnology product portfolio. In addition, she serves as the site head for Bayer’s facility in Berkeley, CA, USA.
Before Bayer, she held the role of Vice President of Pharmaceutical/Technical Operations at Pfizer, Inc., formerly Medivation, where she led the Development and Manufacturing organizations for both biologics and small molecule products. She was also Vice President of R&D at Tanvex Biopharma, Inc., where Dr. Chou led the of rich pipeline projects and provided leadership in R&D, manufacturing, preclinical and clinical functions to enable the success of the company’s IPO. Throughout Dr. Chou’s career, she has achieved significant milestones in protein therapeutic and multiple filings of BLAs and INDs of novel products. She is recognized for her work at Genentech, Wyeth Biopharma/Pfizer and Abbott Bioresearch/AbbVie, and has contributed to the of breakthrough technologies in analytical characterization and the accelerated process and formulation .
Before joining the industry, Dr. Chou was also a research faculty member at Harvard University Medical School, focused on cell biology and neuroscience research. Dr. Chou obtained her Ph.D. from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany.
Senior Vice President, Development Sciences & Regulatory Affairs, Teneobio, Inc
Dr. Iyer has over 20 years of experience in the biotech industry that spans drug discovery, translational research, regulatory interactions and clinical . Prior to joining Teneobio in April 2017, Dr. Iyer was at Abbvie as Global Project Leader in Oncology Clinical Development where she led programs in early . Prior to Abbvie, Dr. Iyer was at Genentech for 11 years during which she participated in and led preclinical and clinical teams in immunology and oncology, resulting in key milestones for several programs. She began her R&D career at Sangstat Medical Corp with over 9 years in discovery and early research. She earned her Ph.D. from University of California at Davis, is a co-author on over 40 publications, has presented at numerous national and international forums and is a co-inventor on 5 patents.
Senior Vice President, Biometrics, Health Economics and
outcome Research, CTI BioPharma
Lixia Wang is Senior Vice President of CTI Biopharma Corp. She is responsible for managing Biometrics, Health Economic and Outcome Research in supporting drug and commercialized. With 24 years’ experience working cross big pharma, and biotech companies, Lixia has increasing responsibilities held multiple leadership positions and successfully supported many products worldwide registrations and reimbursements. Lixia is passionate to use innovation to bring technology, data science to expedite and improve drug . Lixia received his Ph.D. in Biostatistics from School of Public Health, University of South Carolina, had Master in Applied Statistics and Bachelor of Electronic and Computer Engineering.